Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Healthcare use around a first dementia diagnosis in older patients with serious mental illness
Chung, Jamie O.P., Woo, Benjamin K P , Shu, Sara, Shu, Sara

Geriatrics & Gerontology International | July 24, 2024 | Volume: 25 | Issue: 1 | Pages: 128-129

10.1111/ggi.14946 | PMID 39044121 Get It

Adjuvant Intralesional Bevacizumab in Pediatric and Adult Populations With Recurrent Respiratory Papillomatosis: A Systematic Review
Gately, Ursula E. , Zhang, Nan , Karle, William E. , Lott, David G. , Lott, David G

Annals of Otology, Rhinology & Laryngology | July 24, 2024 | Volume: 133 | Issue: 10 | Pages: 841-847

10.1177/00034894241264388 | PMID 39044374 Get It

Objective: Recurrent respiratory papillomatosis (RRP) is a rare disease of the airway for which there is no known cure. Treatment involves the surgical removal or destruction of these lesions. There has been a long-standing debate over the effectiveness of the adjuvant intralesional injection of the immune modifying agent bevacizumab. This study is a systematic review investigating the effect of adjuvant intralesional bevacizumab on patients with laryngeal papillomatosis. The main objective was to assess functional outcomes and efficacy. Data Sources: Pubmed, Google Scholar, and Web of Science. Review Methods: Search words were “intralesional bevacizumab” AND “recurrent respiratory papillomatosis.” Sources were systematically identified using inclusion and exclusion criteria (ie, study publication must post-date 2000, must be peer-reviewed, investigate patients with RRP, apply bevacizumab intralesionally, not systemically). Findings were then collected and analyzed. Results: Ten studies were included for analysis. The majority of these studies found an increase in the surgical interval, voice outcomes, and a decrease in tumor burden in most patients. No studies reported side effects or lasting complications related to the bevacizumab injection. Conclusion: This systematic review provides further evidence for the safety of intralesional bevacizumab injections and their likely positive effect on disease control. Future research would benefit from the implementation of standardized documentation of RRP outcomes.
Indications for cerebral revascularization for moyamoya syndrome in pediatric sickle cell disease determined by Delphi methodology
Robert, Adam , Adelson, P. David, Lang, Shih‐Shan , Grabb, Paul A. , Greene, Stephanie , Leonard, Jeffrey, Magge, Suresh N. , Marupudi, Neena I. , Sillero, Rafael de Oliveira , Smith, Edward R. , Smith, Jodi L. , Strahle, Jennifer M. , Vadivelu, Sudhakar , Wellons, John C. , Wrubel, David, Hatem, Asmaa, Moody, C, Han, Sabrina H. , Millican, Nicklaus , Dain, Aleksandra S. , Beslow, Lauren A. , Aldana, Philipp R. , Montaser, Alaa, Smith, Edward , Hanel, Ricardó A. , Johnston, James M. , Piatt, Joseph H. , Hatem, Asmaa, Montaser, Alaa S. , Pederson, John M.

Journal of Neurosurgery: Pediatrics | July 24, 2024 | Volume: 34 | Issue: 4 | Pages: 402-413

10.3171/2024.5.peds2426 | PMID 39029127 Get It

OBJECTIVE Cerebral revascularization surgery (CRS) has been used to prevent stroke in children with sickle cell disease (SCD) and cerebral vasculopathy (e.g., moyamoya syndrome). While results suggest that it may be an effective treatment, surgical indications have not been well defined. This study sought to determine indications for offering revascularization surgery in centers with established sickle cell programs in the US. METHODS Three sequential surveys utilizing the Delphi methodology were administered to neurosurgeons participating in the Stroke in Sickle Cell Revascularization Surgery study. Respondents were presented with clinical scenarios of patients with SCD and varying degrees of ischemic presentation and vasculopathy, and the group’s agreement to offer surgical revascularization was measured. Consensus was defined as ≥ 75% similar responses. RESULTS The response rate to all 3 surveys was 100%. Seventeen neurosurgeons from 16 different centers participated. The presence of moyamoya collaterals (MMCs) and arterial stenosis matching an ischemic distribution yielded the strongest recommendations to offer surgery. There was consensus to offer revascularization in the presence of MMCs and at least 50% arterial stenosis matching an ischemic distribution. In contrast, there was no consensus to offer revascularization with 50%–70% stenosis not matching an ischemic presentation in the absence of MMCs. The presence of the ivy sign in the distribution of the stenotic artery also contributed to the consensus to offer surgery in certain scenarios. CONCLUSIONS There were several clinical scenarios that attained consensus to offer surgery; the strongest was moderate to severe arterial stenosis that matched the distribution of ischemic presentation in the presence of MMCs. Radiological findings of decreased cerebral flow or perfusion also facilitated attaining consensus to offer surgery. The findings of this study reflect expert opinion about questions that deserve prospective clinical research. Determination of indications for CRS can guide clinical practice and aid the design of prospective studies.
Ubiquitin-Proteasome System in the Different Stages of Dominantly Inherited Alzheimer’s Disease
McDade, Eric , Hassenstab, Jason , Gordon, Brian A. , Benzinger, Tammie L.S. , Shen, Yuanyuan , Wang, Lihua , Sung, Yun Ju , Daniels, Alisha , Xiong, Chengjie , Perrin, Richard J. , Day, Gregory S. , Chhatwal, Jasmeer P. , Huey, Edward D. , Ryan, Natalie S. , Laske, Christoph , Xiong, Chengjie , Roh, Jee Hoon , Lopera, Francisco , Morris, John C. , Gordon, Brian A , Benzinger, Tammie L S , Sung, Yun Ju , Karch, Celeste M , Renton, Alan , Day, Gregory S , Chhatwal, Jasmeer , Ikeuchi, T , Kasuga, Kensaku , Schofield, Peter R , Brooks, William , Xiong, Chengjie , Roh, Jee Hoon , Bateman, Randall J , Cruchaga, Carlos , Hassenstab, Jason , McDade, Eric M , Morris, John C , Liu, Haiyan , Bui, Quoc Van Phu , Timsina, Jigyasha , Karch, Celeste M. , Morris, John M. , Ibanez, Laura , Llibre‐Guerra, Jorge J. , Supnet, Charlene , Xu, Xiong, Berman, Sarah , Ikeuchi, Takeshi , Niimi, Yoshiki , Schofield, Peter R. , Brooks, William S. , Jucker, Mathias , Vöglein, Jonathan , Lopera, Francisco Javier , Bateman, Randall J.

No container title available | July 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4202125/v1 | PMID 39108475 Get It

Abstract This study explored the role of the ubiquitin-proteasome system (UPS) in dominantly inherited Alzheimer’s disease (DIAD) by examining changes in cerebrospinal fluid (CSF) levels of UPS proteins along with disease progression, AD imaging biomarkers (PiB PET, tau PET), neurodegeneration imaging measures (MRI, FDG PET), and Clinical Dementia Rating® (CDR®). Using the SOMAscan assay, we detected subtle increases in specific ubiquitin enzymes associated with proteostasis in mutation carriers (MCs) up to two decades before the estimated symptom onset. This was followed by more pronounced elevations of UPS-activating enzymes, including E2 and E3 proteins, and ubiquitin-related modifiers. Our findings also demonstrated consistent correlations between UPS proteins and CSF biomarkers such as Aβ42/40 ratio, total tau, various phosphorylated tau species to total tau ratios (ptau181/T181, ptauT205/T205, ptauS202/S202, ptauT217/T217), and MTBR-tau243, alongside Neurofilament light chain (NfL) and the CDR®. Notably, a positive association was observed with imaging markers (PiB PET, tau PET) and a negative correlation with markers of neurodegeneration (FDG PET, MRI), highlighting a significant link between UPS dysregulation and neurodegenerative processes. The correlations suggest that the increase in multiple UPS proteins with rising tau levels and tau-tangle associated markers, indicating a potential role for the UPS in relation to misfolded tau/neurofibrillary tangles (NFTs) and symptom onset. These findings indicate that elevated CSF UPS proteins in DIAD MCs could serve as early indicators of disease progression and suggest a link between UPS dysregulation and amyloid plaque, tau tangles formation, implicating the UPS as a potential therapeutic target in AD pathogenesis.
Impact of Workplace Violence Against Emergency Medical Services (EMS)
McGuire, Sarayna S. , Clements, Casey M. , Lampman, Michelle A. , Smith, Olivia A, McGuire, Sarayna S , Smith, Olivia A.

Prehospital Emergency Care | July 23, 2024 | Volume: 29 | Issue: 2 | Pages: 129-137

10.1080/10903127.2024.2381218 | PMID 39042823 Get It

Three-dimensional printing for complex cardiac reoperations: optimising Gerbode defect repairs
Khan, Fazal Wahab , Chopko, Trevor C. , Maltais, Simon, Stulak, John M., Khan, Fazal W, Chopko, Trevor

BMJ Case Reports | July 23, 2024 | Volume: 17 | Issue: 7 | Pages: e260689

10.1136/bcr-2024-260689 | PMID 39043460 Get It

Cardiac fistulas present diagnostical and therapeutical challenges due to their variability in size, shape and pathway. Three-dimensional printing is increasingly used to provide a tactile representation that aids in preoperative planning and patient education. We present the case of a female in her 60s who developed a fistula between the left ventricle, right atrium and coronary sinus 2 years after bioprosthetic valve replacement. We used three-dimensional modelling to better understand her cardiac anatomy and optimise our surgical approach. She was discharged home without deficit following an uneventful postoperative course. Three-dimensional printing can improve patient care through tangible demonstration, preoperative planning and trainee education.
Defining the tipping point for revision reverse shoulder arthroplasty
Buchanan, Timothy R. , Hao, Kévin A. , Cueto, Robert J. , O’Keefe, Daniel S. , Hones, Keegan M. , Krisanda, Emily, Wright, Jonathan O. , Wright, Thomas W. , Struk, Aimee M., S O'Keefe, Daniel , Wright, Jonathan O , Schoch, Bradley S , King, Joseph J , Hao, Kevin A , Hones, Keegan M , Bindi, Victoria E. , Farmer, Kevin W. , Schoch, Bradley S. , King, Joseph J.

Shoulder & Elbow | July 23, 2024 | Volume: 17 | Issue: 4 | Pages: 439-449

10.1177/17585732241263753 | PMID 39552664 Get It

Background This study sought to characterize the tipping point values (the functional scores that patients deem dysfunctional enough to warrant surgery) for patients undergoing first revision reverse total shoulder arthroplasty (rTSA). Methods This study was a retrospective review of a prospectively collected single-institution database of patients undergoing first revision rTSA between August 2015 and December 2019. Tipping point evaluation utilized preoperative scores including the American Shoulder and Elbow Surgeons (ASES), raw and normalized Constant, Shoulder Pain and Disability Index (SPADI), Simple Shoulder Test (SST), and University of California-Los Angeles (UCLA) scores, and active range of motion including abduction, forward elevation (FE), external rotation (ER), and internal rotation score (IR) prior to elective revision rTSA. Results We included 125 revision rTSAs. Tipping points were 37.6 ASES score, 30.5 raw Constant score, 35.5 normalized Constant score, 68.1 SPADI, 3.7 SST, 13.2 UCLA score, 64° abduction, 69° FE, 23° ER, and 3.1 IR. Higher SST was found for older patients and patients with a lower body mass index. Lower abduction and FE tipping points were reported in patients undergoing revision rTSA for rotator cuff failure, unexplained pain, and implant wear. Discussion These tipping points can help surgeons counsel patients regarding when to undergo revision rTSA. Level of evidence Level III; retrospective cohort study; treatment study.
PA-VSD Without MAPCA(s): Review of Long-Term Outcomes and Reinterventions
Stephens, Elizabeth H. , Dearani, Joseph A. , Miranda, William R. , Dearani, Joseph A. , Anderson, Jason H.

World Journal for Pediatric and Congenital Heart Surgery | July 23, 2024 | Volume: 16 | Issue: 2 | Pages: 232-236

10.1177/21501351241254034 | PMID 39043197 Get It

Background Pulmonary atresia with ventricular septal defect without major aortopulmonary collateral arteries (MAPCAs) is an uncommon form of congenital heart disease. As more patients with congenital heart disease live to adulthood, the objective of this article was to review the long-term results of this specific population. Methods A review of the PubMed database was performed using pertinent key words (pulmonary atresia, tetralogy of Fallot, conduit, right ventricle-pulmonary artery) concentrating on studies from 1990-present and published in English. Most studies of pulmonary atresia-ventricular septal defect patients included those with and without MAPCAs. Analysis included examination of the entire cohort, consideration of the proportion of patients with MAPCAs, and any subgroup analysis of the patients without MAPCAs. Results Survival is approximately 80% at ten years and is improved with complete repair and larger pulmonary arteries. Some studies have found genetic syndromes and extracardiac anomalies to impact survival, while others have not. Incomplete repair has been shown to be associated with worse survival. Independent of initial management strategy, patients with pulmonary atresia and ventricular septal defects without MAPCAs require repeat intervention on the right ventricular outflow tract. Hypoplastic pulmonary arteries have been shown to be a risk factor for reintervention, and decreased conduit durability has been shown with younger age at implantation of conduit. Conclusions Long-term outcomes have improved for patients with pulmonary atresia-ventricular septal defect without MAPCAs, with complete repair and adequate pulmonary arteries favorable for survival. Long-term outcomes include reinterventions, both catheter-based and surgical, predominantly on the right ventricular outflow tract.
Phase II clinical trial of PLX038 in patients with platinum resistant ovarian, primary peritoneal and fallopian tube cancer.
Hendrickson, Andrea E. Wahner , Foster, Nathan R. , Clasemann, Tracy, Grudem, Megan E. , Klampe, Carolyn M., Block, Matthew S. , Jatoi, Aminah , Weroha, Saravut J., Choong, Grace M. , Flickinger, Lynn M. , Ashley, Gary W. , Langecker, P., Santi, Daniel V. , Yadav, Siddhartha , Kaufmann, Scott H.

Journal of Clinical Oncology | July 23, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS5630-TPS5630

10.1200/jco.2024.42.16_suppl.tps5630 Get It

TPS5630 Background: Platinum-resistant ovarian cancer (PROC) portends a poor prognosis and, although treatments are available, response rates are low. Previous studies have demonstrated that DNA topoisomerase I (TOP1) inhibitors exhibit clinical activity in PROC. Irinotecan also has a 15-25% response rate in some studies of platinum-resistant epithelial ovarian cancer but does not have FDA approval for this indication. Additional studies in preclinical models suggest that TOP1 poisons are more active if administered at low doses on prolonged schedules. PLX038 is a long-acting prodrug of the potent TOP1 inhibitor SN-38. In PLX038, SN-38 is covalently conjugated to circulating polyethylene glycol and is slowly released at a constant rate to provide the active agent with a long half-life, a low Cmax and very high exposure – important facets for optimal safety and efficacy of this drug. Further, in preclinical studies the nanoparticle prodrug accumulates and is retained in tumors, where it slowly releases the SN-38. Methods: This single arm, phase 2 clinical trial is open at Mayo Clinic in Rochester, MN. The primary endpoint is overall response rate and secondary endpoints include progression-free survival and assessment of tolerability of PLX038. Correlative goals include i) measurement of TOP1-DNA covalent complexes in tumor biopsies and circulating tumor cells to assess successful target engagement; ii) assessment of homologous recombination status and SLFN11 expression for correlation with tumor response rate; and iii) pharmacokinetics of SN-38 and SN-38G as well as their association with GI toxicity. Assessment of gut microbiota and association with GI toxicity profile are also being investigated. Eligible patients include women with platinum resistant high grade serous ovarian, primary peritoneal, and fallopian tube cancer who have received fewer than two prior chemotherapy regimens in the platinum-resistant setting. All patients must have an ECOG performance status of 0, 1, or 2 and adequate bone marrow, renal, and hepatic function. As of January 31, 2024, 12 of planned 37 patients have enrolled. Clinical trial information: NCT05465941 .